SOHO Annual Meeting | Conferences

Exploring CAR T-Cell Therapies in the Indolent Lymphoma Setting

September 10, 2021

Early data have shown the promise of CD19-directed chimeric antigen receptor T cells for indolent lymphoma treatment, but longer follow-up is needed to determine if these responses represent cures in these historically difficult-to-treat malignancies.

IGHV and TP53 Remain Important Prognostic CLL Biomarkers

September 09, 2021

IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia, despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients.